Endava is trading at $2.89, down 5.56%, with no credible, fresh company-specific announcement found to explain the opening decline.
- Guggenheim downgraded Endava to Neutral on May 27, citing weak results and elongated deal cycles, but the call is stale rather than a September 8 catalyst.
- Broader markets are mixed, so macro sentiment does not clearly explain the move.